Health & Fitness
Health and Fitness
Health and Fitness
Fri, October 28, 2011
Thu, October 27, 2011
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Adamis Pharmaceuticals Corp.
NEW YORK--([ BUSINESS WIRE ])--Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview (EIO) on Adamis Pharmaceuticals Corp. (OTCBB:ADMP). The full 52-page report can be found at [ www.crystalra.com ].
Adamis Pharmaceuticals Corp. ("Adamis" or "the Company") is an emerging biopharmaceutical company combining specialty pharmaceuticals and biotechnology to create treatment options in the areas of allergy, respiratory, oncology, and immunological disorders as well as for infectious diseases. Adamis' initiatives include a prefilled single-dose epinephrine syringe for injection ("PFS") for which the Company is submitting a New Drug Application (NDA) in the U.S. The epinephrine PFS is used for the emergency treatment of anaphylaxis and may have competitive advantages over existing epinephrine products due to its low cost and user friendliness. In addition, Adamis is developing inhaled therapeutics for allergic rhinitis, asthma, and COPD under a December 2010 agreement with Beximco Pharmaceuticals Ltd., a Bangladesh conglomerate with over 400 products ranging from allergy to oncology.
In April 2011, Adamis' biotechnology unit completed the acquisition of a novel technology forming the basis for a prostate cancer vaccine called TeloB-VAX. TeloB-VAX is scheduled to enter Phase II studies, for which an Investigational New Drug (IND) application will likely be filed in the fourth quarter 2011. Going forward, the vaccine platform may be able to treat other tumor types, such as lung, breast, and colon cancers, as well as viral diseases, including chronic hepatitis, human papilloma virus (HPV), and influenza.
Adamis is also advancing three first-in-class compounds (APC-100, -200, -300) to treat prostate cancer. Two of these have previously received the National Cancer Institute's (NCI) RAPID Award given to promising new cancer drugs. A Phase I/IIa study of APC-100 has already begun, and Adamis expects to submit an IND to begin studies with APC-200 in the first quarter 2012. In addition, through Adamis' reverse merger, it obtained a contraceptive product (C31G) that has completed a successful Phase III study and was shown to have met primary and secondary endpoints.
Be the first to hear about Crystal Researchas new report releases and upcoming media coverage. Follow us on Twitter at [ http://twitter.com/crystalresearch ] or visit [ http://crystalra.com/blog/ ].
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality research on small- and mid-cap companies. The firm is led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the international financial media for his years of work on Wall Street and for providing consistent award-winning analyses and developing long-term relationships on both the buy-side and sell-side. He has been consistently ranked on Wall Street among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally, Mr. Kraws has been 5-Star Ranked for top biotechnology stock performance by Starmine.
Crystal Research Associates' unique and novel product, the Executive Informational Overview (EIO), is free of investment ratings, target prices, and forward-looking financial models. The EIO presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, West Palm Beach, Montral, and Toronto. Crystal Research Associates has been compensated by the Company in cash of forty-five thousand U.S. dollars and three hundred thousand warrants/options for its services in creating the base report, for quarterly updates, and for printing costs.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, potential applications of the Companyas technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words awill,a abelieves,a aplans,a aanticipates,a aexpects,a aestimates,a and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Companyas periodic reports, including forms filed with the SEC.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.
